Pulmatrix (PULM) Stock Price, News & Analysis

Company Overview

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory and other serious diseases. The company’s approach is designed to deliver medicines directly to the lungs, potentially improving local drug exposure while limiting systemic side effects.

Pulmatrix’s technology platform, iSPERSE, is an engineered dry-powder formulation designed to enable the inhalation of a broad range of drug compounds. The platform has been used in the development of products including PUR1900, an inhaled formulation of itraconazole being investigated for respiratory fungal infections such as allergic bronchopulmonary aspergillosis, and other investigational therapies targeting pulmonary and related conditions.

Based in Lexington, Massachusetts, Pulmatrix has historically focused on advancing inhaled treatments through preclinical and clinical development, while pursuing potential partnerships and commercialization opportunities. Its programs and corporate priorities may change as clinical data, regulatory decisions and financing conditions evolve.

Key Stats

• Today's Range: $1.45 to $1.59
• 50-Day Range: $1.36 to $1.74
• 52-Week Range: $1.16 to $5.50
• Volume: 22,397 shs
• Average Volume: 41,119 shs
• Market Capitalization: $5.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Pulmatrix Stock Analysis - MarketRank™

Pulmatrix scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Pulmatrix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Pulmatrix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pulmatrix is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pulmatrix is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Pulmatrix has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.53% of the float of Pulmatrix has been sold short.

Short Interest Ratio / Days to Cover

Pulmatrix has a short interest ratio ("days to cover") of 1.27, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Pulmatrix has recently increased by 174.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pulmatrix does not currently pay a dividend.

Dividend Growth

Pulmatrix does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 1 people have added Pulmatrix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pulmatrix insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.62% of the stock of Pulmatrix is held by insiders.

Percentage Held by Institutions

11.84% of the stock of Pulmatrix is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PULM
• CIK: 1574235
• Web: www.pulmatrix.com
• Phone: (781) 357-2333
• Fax: 707-525-9906
• Employees: 2
• Year Founded: 2003

Profitability

• EPS (Trailing Twelve Months): ($1.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.16 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -125.65%
• Return on Assets: -95.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.70
• Quick Ratio: 4.70

Sales & Book Value

• Annual Sales: $7.81 million
• Price / Sales: 0.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.45 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 3,650,000
• Free Float: 3,629,000
• Market Cap: $5.48 million
• Optionable: Not Optionable
• Beta: 1.93